Latest Genetic Disease Therapeutics News

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its Phase 1b trial of PYC-003 for Polycystic Kidney Disease, alongside regulatory clearance for an Open-Label Extension allowing continuous dosing up to 24 months.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing of its investigational drug PYC-001 for Autosomal Dominant Optic Atrophy from single to multiple doses, marking a key step in its clinical development.

PYC Therapeutics has launched a substantial $653 million equity raise to fund clinical trials for four promising drug candidates targeting genetic diseases. This capital injection aims to advance the company’s pipeline through critical human efficacy milestones.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its PYC-003 clinical trial and will soon begin dosing patients with Polycystic Kidney Disease, marking a pivotal step forward.